Athenex presents data from oral paclitaxel + pembrolizumab phase 1 study at esmo 2021

Safety data help establish part b dose expansion and phase 2 dose; data showed encouraging anti-tumor activity (4 pr out of 8 evaluable patients) in nsclc patients who failed prior pd1/pdl1 therapies safety data help establish part b dose expansion and phase 2 dose; data showed encouraging anti-tumor activity (4 pr out of 8 evaluable patients) in nsclc patients who failed prior pd1/pdl1 therapies
ATNX Ratings Summary
ATNX Quant Ranking